Skyline Shares recently disclosed its 2025 performance forecast, projecting an annual net profit attributable to shareholders of listed companies ranging from 70 million to 105 million yuan, marking a significant turnaround from the net loss of 1.361 billion yuan in the same period last year. The improvement in performance is primarily attributed to the recovery of two core businesses. On one hand, driven by the rapid growth in demand for new energy vehicles and energy storage, the sales price of the company's core product, lithium hexafluorophosphate, rebounded in the fourth quarter of 2025, leading to a notable recovery in profitability. This not only resulted in a profitable quarter but also successfully offset the losses incurred in the first three quarters, becoming a key driver of the annual performance. However, the company's adherence to contractual obligations, including the execution of some long-term low-price orders, somewhat constrained its profitability. On the other hand, the operational performance of its subsidiary, Xinte Chemical, also improved. The market conditions for its main product, sodium hypophosphite, recovered in the fourth quarter of 2025, with both sales prices and gross profit margins rising, ending the product's prolonged loss-making trend and contributing significantly to the company's overall performance. It is worth noting that despite the recovery in Xinte Chemical's profitability in the fourth quarter, it still fell short of its 2025 performance target. According to the previous performance commitment and acquisition agreement, the original shareholders of Xinte Chemical are required to compensate the company for the performance shortfall, with the relevant compensation amount to be recorded as non-recurring gains or losses. Additionally, based on the principle of prudence, the company conducted preliminary tests and plans to provision for partial goodwill impairment, which will correspondingly impact its performance.